Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe. This initiative is a critical component of Regentis' European commercialization strategy, supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing.
GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair. The company believes that expanding physician familiarity with the technology will support adoption as the product enters broader clinical use. The training program aims to equip surgeons with the skills necessary to perform the implant procedure effectively, which is essential for successful patient outcomes and market acceptance.
The importance of this announcement lies in its potential to address a significant unmet medical need. According to the company, approximately 470,000 cases for cartilage knee repair occur annually in the U.S., where no off-the-shelf treatment is available. GelrinC, a cell-free, off-the-shelf hydrogel, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This technology could offer a new treatment option for patients suffering from knee cartilage lesions, potentially reducing the need for more invasive surgeries.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The company's focus on orthopedic treatments positions it in a growing market for minimally invasive, off-the-shelf solutions.
The training initiative also underscores Regentis' commitment to surgeon education, which is often a key factor in the adoption of new medical technologies. By establishing Centers of Excellence, the company aims to create a community of skilled practitioners who can share knowledge and best practices, thereby accelerating the uptake of GelrinC across Europe. The full press release is available at https://ibn.fm/QOWWK.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. Investors should not place undue reliance on these statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law. For more information, refer to the disclaimer at http://IBN.fm/Disclaimer.
